PharmRep Direct from the editors of Pharmaceutical Representative

June 25, 2010 Issue 41 Vol. 8	www.pharmrep.com
Contact Editor: Reid Paul

Pfizer Pulls Leukemia Treatment
Pfizer was forced (voluntarily) to put the kibosh on a fast-tracked Wyeth drug after some not-so-favorable postmarket data. Was this a good catch or an endemic problem with expedited drugs?
» MORE

GSK Scores High in Global Market Access
A new global report looks at which pharma companies are tops when it comes to offering medicines in emerging markets. Some of the big players are inching forward in a move towards access and transparency.
» MORE

HTA Concerns from European Drug Agency
The EMA's Thomas Lönngren has gone public with his disquiet over organizations such as NICE. But pharma still needs more allies to fight what it sees as the failings of the health technology assessment bodies, says Pharm Exec Europe's Brussels correspondent, Reflector.
» MORE

Certified Letter
The Medical Representative Certification Commission is embarking on a new mission to rebuild rep’s trust in the eyes of physicians. Pharm Rep examines MRCC’s progress and asks, will it work?
» MORE

Physicians Stay Put
A new study indicates that doctors are no longer switching offices—largely due to current economic woes. What does this mean for sales reps? Pharm Exec interviews SK&A to find out more about its survey.
» MORE

The Fine Art of Selling
Great salespeople are passionate ambassadors of excellence argues a regional district sales manager
» MORE

When the Bubble Burst
Between 1995 and 2006 the number of sales reps ballooned to more than 100,000 amid blockbusters and new marketing tactics. Then the model broke. Can pharma learn from its mistakes?
» MORE

GSK Settles Paxil Suits

FDA Caught Napping Over Sleeping Pill Advertising

AZ Settles Price Fixing Suit for $103 Million

Follow Pharm Rep on Twitter

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.